STAR-0215 is under clinical development by Astria Therapeutics and currently in Phase II for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency). According to GlobalData, Phase II drugs for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STAR-0215’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

STAR-0215 overview

STAR-0215 is under development for the treatment of hereditary angioedema. The drug candidate acts by targeting plasma kallikrein. It is administered through subcutaneous route.

Astria Therapeutics overview

Astria Therapeutics (Astria), formerly Catabasis Pharmaceuticals, is a clinical-stage biopharmaceutical company. The company discovers, develops and commercializes medicines for the treatment of multiple diseases. It develops its product candidates using its proprietary safely metabolized and rationally targeted (SMART) Linker drug discovery platform for rare diseases, among others. Astria product candidate edasalonexent CAT-1004, currently under Phase 3 trial, is an oral small molecule intended for the treatment of Duchenne muscular dystrophy. CAT-5571, an activator of autophagy and the company’s lead product under preclinical stage, is an oral small molecule for the treatment of cystic fibrosis. The company’s CAT-4001 is used for the treatment of neurodegenerative diseases such as Friedreich’s ataxia and amyotrophic lateral sclerosis (ALS). Astria is headquartered in Cambridge, Massachusetts, the US

For a complete picture of STAR-0215’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.